Benz CC - Search Results

1

Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance.

DeGregorio MW, Ford JM, Benz CC, Wiebe VJ. DeGregorio MW, et al. Among authors: benz cc. J Clin Oncol. 1989 Sep;7(9):1359-64. doi: 10.1200/JCO.1989.7.9.1359. J Clin Oncol. 1989. PMID: 2527971 Clinical Trial.

2

Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer.

Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW. Wiebe VJ, et al. Among authors: benz cc. Cancer Chemother Pharmacol. 1990;25(4):247-51. doi: 10.1007/BF00684880. Cancer Chemother Pharmacol. 1990. PMID: 2136809 Clinical Trial.

3

Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers.

Ford JM, Hait WN, Matlin SA, Benz CC. Ford JM, et al. Among authors: benz cc. Cancer Lett. 1991 Jan;56(1):85-94. doi: 10.1016/0304-3835(91)90198-q. Cancer Lett. 1991. PMID: 2004358 Free article.

4

Clinical pharmacokinetics of drugs used in the treatment of breast cancer.

Wiebe VJ, Benz CC, DeGregorio MW. Wiebe VJ, et al. Among authors: benz cc. Clin Pharmacokinet. 1988 Sep;15(3):180-93. doi: 10.2165/00003088-198815030-00003. Clin Pharmacokinet. 1988. PMID: 3052986 Review.

5

Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity.

Benz C, Gandara D, Miller B, Drakes T, Monroe S, Wilbur B, DeGregorio M. Benz C, et al. Cancer Treat Rep. 1987 Mar;71(3):283-9. Cancer Treat Rep. 1987. PMID: 3493069

6

Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers.

Benz CC, Keniry MA, Ford JM, Townsend AJ, Cox FW, Palayoor S, Matlin SA, Hait WN, Cowan KH. Benz CC, et al. Mol Pharmacol. 1990 Jun;37(6):840-7. Mol Pharmacol. 1990. PMID: 2193225

7

Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response.

Benz C, DeGregorio M, Saks S, Sambol N, Holleran W, Ignoffo R, Lewis B, Cadman E. Benz C, et al. Cancer Res. 1985 Jul;45(7):3354-8. Cancer Res. 1985. PMID: 4005858

8

Effect of de novo purine synthesis inhibitors on 5-fluorouracil metabolism and cytotoxicity.

Cadman E, Benz C, Heimer R, O'Shaughnessy J. Cadman E, et al. Biochem Pharmacol. 1981 Sep 1;30(17):2469-72. doi: 10.1016/0006-2952(81)90343-9. Biochem Pharmacol. 1981. PMID: 21043247

9

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Baselga J, et al. Among authors: benz cc. J Clin Oncol. 1996 Mar;14(3):737-44. doi: 10.1200/JCO.1996.14.3.737. J Clin Oncol. 1996. PMID: 8622019 Clinical Trial.

10

Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.

Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens JA, Eppenberger-Castori S. Eppenberger U, et al. J Clin Oncol. 1998 Sep;16(9):3129-36. doi: 10.1200/JCO.1998.16.9.3129. J Clin Oncol. 1998. PMID: 9738585

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

226 results

Search Page

Filters